Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Ranibizumab dose-capping scheme proposed

  • Comment
THE NHS will pay for a maximum of 14 injections of ranibizumab (Lucentis) per eye for patients with macular degeneration, under new draft guidelines launched today.
A consultation on the dose-capping scheme drawn up by NICE begins today, which recommends the manufacturer pays if any further doses are needed.

Responses to an earlier consultation criticised proposals recommending treatment of only the second affected eye.

NICE now recommends treating the first eye to come to clinical attention. Andrew Dillon, chief executive of NICE, said: ’14 injections should result in stable vision for most patients and improved vision for around a quarter of patients.’

Dr Lorna Layward, research into ageing manager of Help the Aged, said: ‘[This] is a potentially life-altering treatment for over 50,000 people who experience the more aggressive ‘wet’ form of the condition.’
  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs